Pyrilamine and O-desmethylpyrilamine detection in equine serum and urine.

The research article investigates the effects of Pyrilamine, a human and veterinary medicine, when administered to horses, and its lingering effects that may potentially impact a horse race. The researchers performed tests on blood and urine samples of three horses over a period of 13 days and employed two methods – enzyme-linked immunosorbent assay and gas chromatography-mass spectrometry – for detection and quantification of the drug and its metabolites.

Objective and Methodology

• The researchers aimed to understand the effectiveness and residual impact of Pyrilamine. Notably, the drug, also known as mepyramine, is an H1-receptor antagonist with the potential to affect the central nervous system of horses, thereby possibly affecting the outcome of a horse race.
• Three horses were administered a single oral dosage of Pyrilamine (300 mg/horse). Subsequently, blood and urine samples were collected at various intervals across 13 days, starting from the moment of drug administration.
• The Pyrilamine enzyme-linked immunosorbent assay (ELISA) kit was employed for initial screening of the samples. For further confirmation and quantification, the study utilized a newly developed gas chromatography-mass spectrometry (GC-MS) method that could gauge pyrilamine levels and its major metabolite, O-desmethylpyrilamine, using chlorpromazine as an internal standard.
• Urine specimens were hydrolyzed using beta-glucuronidase.

Key Findings

• Pyrilamine was only found in serum in low concentrations (4-123 ng/mL) up to six hours after drug administration, but was not discovered at all in the urine samples.
• The peak concentrations of pyrilamine in the serum varied among the three horses, with horse #1, #2, and #3 peaking at 15 minutes, 30 minutes, and 1 hour, respectively.
• Using ELISA, the researchers were able to detect pyrilamine and its metabolites in urine samples for extended durations (four days in one horse and up to nine days in two other animals).
• GC-MS method of screening led to the detection of O-desmethylpyrilamine, the major metabolite of pyrilamine, in urine for 11 days in horse #1, four days in horse #2, and nine days in horse #3.
• The researchers noted that while pyrilamine was quickly released from the bloodstream, the metabolite remained present in the urine for several days following its administration.

Conclusion and Implications

• The research indicated that a positive urine sample for O-desmethylpyrilamine, the primary metabolite of pyrilamine, does not necessarily mean that the drug is still active in the horse’s system.
• This information is crucial for regulators in evaluating laboratory results, as it could potentially impact the outcome of a horse race.